Efanesoctocog alfa 引发的功能性血凝块形成与重组凝血因子 VIII 无法区分
本研究在血友病 A 患者血浆及血友病 A 小鼠中比较 efanesoctocog alfa 与重组凝血因子 VIII(rFVIII)的止血潜力。结果显示,等浓度(最高 1 IU/ml)两药在血浆中引致的剂量依赖性纤维蛋白聚合动力学相似,在组织型纤溶酶原激活剂(tPA)存在下血凝块稳定性相似;小鼠单次静脉注射 50、100 或 150 IU/kg 两药后血小板累积呈剂量依赖性增加且动力学相似。结论为等效剂量下两药促进纤维蛋白血凝块形成和损伤诱导血小板累积的效力相似,efanesoctocog alfa 的止血潜力与 rFVIII 无法区分。
要点
- 等浓度(最高 1 IU/ml)efanesoctocog alfa 与 rFVIII 在血友病 A 患者血浆中引致的剂量依赖性纤维蛋白聚合动力学相似。
- 在 tPA 存在下,两药形成的血凝块稳定性相似。
- 血友病 A 小鼠单次静脉注射 50、100 或 150 IU/kg 两药后血小板累积呈剂量依赖性增加,且两药血小板沉积动力学相似。
核心结论
- 等效剂量的 efanesoctocog alfa 与 rFVIII 在促进纤维蛋白血凝块形成和损伤诱导血小板累积方面效力相似。
- Efanesoctocog alfa 的止血潜力与 rFVIII 无法区分。
研究设计与样本
- 体外研究:在血友病 A 患者血浆中测定 efanesoctocog alfa 与 rFVIII 对纤维蛋白生成的剂量依赖性效应。
- 体内研究:采用活体显微镜和重复隐静脉激光诱导损伤,在血友病 A 小鼠中评估两药对损伤诱导血小板累积的影响。
主要发现
- 在血友病 A 患者血浆中加入等浓度(最高 1 IU/ml)的 efanesoctocog alfa 或 rFVIII,两药引致的剂量依赖性纤维蛋白聚合动力学相似。
- 在组织型纤溶酶原激活剂(tPA)存在下,两药形成的血凝块稳定性相似。
- 血友病 A 小鼠在重复隐静脉激光诱导损伤前不久单次静脉注射 efanesoctocog alfa 或 rFVIII(50、100 或 150 IU/kg),血小板累积随时间呈剂量依赖性增加。
- 两药的血小板沉积动力学相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Factor VIII (FVIII) binding to endogenous von Willebrand factor (VWF) has constrained half-life extension of recombinant FVIII (rFVIII) products for hemophilia A. Efanesoctocog alfa (rFVIIIFc-VWF-XTEN; BIVV001) is a novel fusion protein designed to decouple FVIII from VWF in circulation and maximize half-life prolongation by XTEN® polypeptides and Fc fusion. FVIII, VWF, and platelets interact to achieve normal hemostasis. Thus, bioengineered FVIII replacement products, such as efanesoctocog alfa, require comprehensive assessment of their hemostatic potential. OBJECTIVES: We compared functional clot formation and injury-induced platelet accumulation between efanesoctocog alfa and rFVIII. PATIENTS/METHODS: The hemostatic potential of efanesoctocog alfa and rFVIII were assessed by measuring their dose-dependent effects on in vitro fibrin generation in hemophilic plasma and in vivo injury-induced platelet accumulation using intravital microscopy and repeat saphenous vein laser-induced injuries in hemophilia A mice. RESULTS: Equal concentrations of efanesoctocog alfa or rFVIII (up to 1 IU/ml) added to plasma from patients with hemophilia A elicited similar kinetics for dose-dependent fibrin polymerization between factor products. In the presence of tissue plasminogen activator (tPA), clots formed had similar stability between products. Single intravenous doses (50, 100, or 150 IU/kg) of efanesoctocog alfa or rFVIII shortly before repeat saphenous vein laser-induced injuries increased platelet accumulation over time in a dose-dependent manner in hemophilia A mice. Platelet deposition kinetics were similar between products. CONCLUSIONS: Equivalent doses of efanesoctocog alfa and rFVIII had similar efficacy in promoting fibrin clot formation and injury-induced platelet accumulation. The hemostatic potential of efanesoctocog alfa was indistinguishable from that of rFVIII.
引用
- Demers M, Aleman MM, Kistanova E, et al. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII. J Thromb Haemost. 2022. PMID: 35466511. doi:10.1111/jth.15741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。